What amount sold does BridgeHealth Pharmaceuticals, Inc. report in Form D filings?

The latest linked filings report $3.5M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was BridgeHealth Pharmaceuticals, Inc.'s most recent SEC filing?

BridgeHealth Pharmaceuticals, Inc.'s most recent Form D filing was on 2026-11-05.

How many investors does BridgeHealth Pharmaceuticals, Inc. have?

The most recent Form D filing lists 5 investor(s).

What type of securities does BridgeHealth Pharmaceuticals, Inc. offer?

BridgeHealth Pharmaceuticals, Inc.'s SEC Form D filings indicate equity offerings.

BridgeHealth Pharmaceuticals, Inc.

CIK: 0002162724·Pharmaceuticals·WOBURN, MA·Corporation·Founded 2025

Reported Sold

$3,500,000

Total Filings

Identified Offerings

Last Filed

Nov 5, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Nov 5, 2026Form D — New notice

Reported sold: $3,500,000 · Target: $3,500,000

Rule 506(b)·5 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$3,500,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Neal Muni

Related Person

Appears on 1 filing

Indu Muni

Related Person

Appears on 1 filing

Howard Ackerman

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 5, 2026	New	$3,500,000	$3,500,000	5

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Andros Medicines Inc.

Pharmaceuticals

Offering target: $5,049,999

Filed Jul 1, 2026